Mike Blecker, Scientific Director of Medical Affairs of Solid Tumors at Incyte, shared a post on LinkedIn:
“Reflecting on 2025, it was another remarkable year filled with significant achievements. A highlight was receiving the USMA Enterprise Award. I had the opportunity to work on various cross-functional projects, contribute to evidence generation and content development, and engage in Omni channel initiatives.
Collaborating with incredibly talented colleagues at my company was a rewarding experience. I also built strong relationships with leading clinicians in the US and globally, who are dedicated to patient care and advancing oncology research.
As I enter 2026, I am making the decision to let go of my board certification (BCPS), something I have held onto for over a decade. While I have continued to excel in my current role and expand my expertise in solid tumor therapies, I recognize that my career path has evolved significantly since my hospital days. This decision, though challenging, aligns with my professional journey.
What are you looking forward to in the new year?
Cheers to 2026!”
For more oncology insights, you can explore additional content on OncoDaily.